Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation

• Published in: Transplant infectious disease Vol. 15; no. 5; pp. 449 - 456
• Main Authors: Heinz, W.J., Einsele, H., Helle-Beyersdorf, A., Zirkel, J., Grau, A., Schirmer, D., Lenker, U., Klinker, H.
• Format: Journal Article
• Language: English
• Published: Denmark Blackwell Publishing Ltd 01.10.2013; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Antifungal Agents - blood; Antifungal Agents - therapeutic use; Aspergillosis - drug therapy; Aspergillosis - microbiology; Aspergillosis - prevention & control; drug concentration; Female; fungal infection; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Male; Middle Aged; Mycoses - drug therapy; Mycoses - microbiology; Mycoses - prevention & control; posaconazole; Retrospective Studies; stem cell transplantation; Triazoles - blood; Triazoles - therapeutic use; Young Adult; posaconazole; fungal infection; stem cell transplantation; drug concentration

Introduction Posaconazole is recommended for prophylaxis of fungal infections and for salvage therapy of invasive aspergillosis after stem cell transplantation. An impact of drug concentration on efficacy has been suggested. Methods In this study, we investigated serum levels of posaconazole in 262...